SCHEMBL6500352

SCHEMBL6500352

CCCC[C@H](N)C(=O)N(C)OC

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 5/20 0.43
SLC15A1 P46059 1/20 0.43
SLC1A2 P43004 2/20 0.41
SLC1A1 P43005 2/20 0.41
SLC1A3 P43003 1/20 0.41
DPP4 P27487 4/20 0.40
DPP8 Q6V1X1 4/20 0.40
DPP9 Q86TI2 4/20 0.40
METAP1 P53582 1/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
ERAP2 Q6P179 2/20 0.36
LNPEP Q9UIQ6 2/20 0.36
GRIK1 P39086 1/20 0.36
GRIK2 Q13002 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9045357 1.00 DPP7 (0.43) DPP7SLC15A1SLC1A2SLC1A1SLC1A3
SCHEMBL753367 0.89 SLC1A2 (0.37) DPP7SLC1A2SLC1A1SLC1A3DPP4
SCHEMBL4594561 0.80 DPP7 (0.48) DPP7SLC15A1SLC1A2SLC1A1SLC1A3
SCHEMBL6628997 0.80 FAAH (0.38) SLC1A2SLC1A1SLC1A3DPP4DPP9
SCHEMBL4594803 0.80 DPP7 (0.48) DPP7SLC15A1SLC1A2SLC1A1SLC1A3
SCHEMBL6629003 0.80 FAAH (0.38) SLC1A2SLC1A1SLC1A3DPP4DPP9
SCHEMBL8207300 0.80 CYP1A2 (0.39)
SCHEMBL18099967 0.79 CA1 (0.42) SLC15A1CA1CA2
SCHEMBL21625667 0.78 CA2 (0.56) SLC1A2SLC1A1SLC1A3CA1CA2
SCHEMBL8552305 0.78 CA2 (0.47) SLC1A2SLC1A1SLC1A3CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6858636-B2 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO. (US) 2005-02-22 US disclosed
US-20040048911-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G. D. SEARLE & CO. 2004-03-11 US disclosed
US-6630497-B2 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO 2003-10-07 US disclosed
US-6492397-B1 SUCH AS 1-PROPYL-4-BUTYL-1,3-DIHYDRO-3-((5-(2-(1H-TETRAZOL-5-YL)PHENYL)-2 -PYRIDINYL)METHYL)-2H-IMIDAZOL-2-ONE; ANGIO-TENSIN II ANTAGONISTS; CIRCULATORY DISORDERS; HYPERTENSION, CONGESTIVE HEART FAILURE PHARMACIA CORPORATION 2002-12-10 US disclosed
US-20020038035-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO. 2002-03-28 US disclosed
EP-0690854-B1 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS SEARLE & CO (US) 2000-07-12 EP disclosed
EP-0978515-A2 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists G.D. SEARLE & CO. (US) 2000-02-09 EP disclosed
EP-0508393-B1 N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders SEARLE & CO (US) 1999-06-02 EP disclosed
EP-0579766-B1 N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS SEARLE & CO (US) 1999-06-02 EP disclosed
US-5861420-A ANGIOTENSIN II ANTAGONISTS G. D. SEARLE & CO. (US) 1999-01-19 US disclosed
US-5441970-A Administering angiotensin II antagonists to treat congestive heart failure or hypertension G. D. SEARLE & CO. (US) 1995-08-15 US disclosed
WO-1994021629-A1 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1994-09-29 WO disclosed
EP-0579766-A1 N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1994-01-26 EP disclosed
US-5238952-A Treating glaucoma disorders G. D. SEARLE & CO. (US) 1993-08-24 US disclosed
EP-0555331-A1 N-SUBSTITUTED IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS. SEARLE & CO (US) 1993-08-18 EP disclosed
US-5164403-A Hypotensive agents, cardiovascular disorders G. D. SEARLE & CO. (US) 1992-11-17 US disclosed
WO-1992017469-A2 N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1992-10-15 WO disclosed
EP-0508393-A1 N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders G.D. Searle & Co. (US) 1992-10-14 EP disclosed
WO-1992007834-A1 N-SUBSTITUTED IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1992-05-14 WO disclosed
US-5087634-A N-substituted imidazol-2-one compounds for treatment of circulatory disorders G. D. SEARLE & CO. (US) 1992-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020038035-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders AGTR1, AGTR2, REN DPP7 1187/4885SLC15A1 1745/4885SLC1A2 1159/4885
US-20040048911-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders AGTR1, AGTR2, REN DPP7 1187/4885SLC15A1 1745/4885SLC1A2 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.